|
1
|
Ma S, Chan KW and Guan XY: In search of
liver cancer stem cells. Stem Cell Rev. 4:179–192. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tomuleasa C, Soritau O, Rus-Ciuca D, et
al: Isolation and characterization of hepatic cancer cells with
stem-like properties from hepatocellular carcinoma. J
Gastrointestin Liver Dis. 19:61–67. 2010.PubMed/NCBI
|
|
3
|
Ricci-Vitiani L, Lombardi DG, Pilozzi E,
et al: Identification and expansion of human
colon-cancer-initiating cells. Nature. 445:111–115. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lee TK, Castilho A, Ma S and Ng IO: Liver
cancer stem cells: implications for a new therapeutic target. Liver
Int. 29:955–965. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mackillop WJ, Ciampi A, Till JE and Buick
RN: A stem cell model of human tumor growth: implications for tumor
cell clonogenic assays. J Natl Cancer Inst. 70:9–16.
1983.PubMed/NCBI
|
|
6
|
Gupta PB, Chaffer CL and Weinberg RA:
Cancer stem cells: mirage or reality? Nat Med. 15:1010–1012. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chiba T, Kita K, Zheng YW, et al: Side
population purified from hepatocellular carcinoma cells harbors
cancer stem cell-like properties. Hepatology. 44:240–251. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yang ZF, Ho DW, Ng MN, et al: Significance
of CD90+ cancer stem cells in human liver cancer. Cancer Cell.
13:153–166. 2008.
|
|
9
|
Ma S, Chan KW, Hu L, et al: Identification
and characterization of tumorigenic liver cancer stem/progenitor
cells. Gastroenterology. 132:2542–2556. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhu Z, Hao X, Yan M, et al: Cancer
stem/progenitor cells are highly enriched in CD133+CD44+ population
in hepatocellular carcinoma. Int J Cancer. 126:2067–2078. 2010.
|
|
11
|
Kimura O, Takahashi T, Ishii N, et al:
Characterization of the epithelial cell adhesion molecule (EpCAM)+
cell population in hepatocellular carcinoma cell lines. Cancer Sci.
101:2145–2155. 2010.
|
|
12
|
Yang W, Yan HX, Chen L, et al:
Wnt/beta-catenin signaling contributes to activation of normal and
tumorigenic liver progenitor cells. Cancer Res. 68:4287–4295. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Haraguchi N, Ishii H, Mimori K, et al:
CD13 is a therapeutic target in human liver cancer stem cells. J
Clin Investig. 120:3326–3339. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Salnikov AV, Kusumawidjaja G, Rausch V, et
al: Cancer stem cell marker expression in hepatocellular carcinoma
and liver metastases is not sufficient as single prognostic
parameter. Cancer Lett. 275:185–193. 2009. View Article : Google Scholar
|
|
15
|
Pellegrino R, Brusasco V, Viegi G, et al:
Definition of COPD: based on evidence or opinion? Eur Respir J.
31:681–682. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pharmacopoeia Commission of People’s
Republic of China. Pharmacopoeia of the Peoples Republic of China.
1. China Chemical Industry Press; Beijing: 2010, (In Chinese).
|
|
17
|
Ye Q, Zhang QY, Zheng CJ, Wang Y and Qin
LP: Casticin, a flavonoid isolated from Vitex rotundifolia,
inhibits prolactin release in vivo and in vitro. Acta Pharmacol
Sin. 31:1564–1568. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shen JK, Du HP, Yang M, Wang YG and Jin J:
Casticin induces leukemic cell death through apoptosis and mitotic
catastrophe. Ann Hematol. 88:743–752. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang J, Yang Y, Tian L, Sheng XF, Liu F
and Cao JG: Casticin-induced apoptosis involves death receptor 5
upregulation in hepatocellular carcinoma cells. World J
Gastroenterol. 17:4298–4307. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Feng X, Zhou Q, Liu C and Tao ML: Drug
screening study using glioma stem-like cells. Mol Med Rep.
6:1117–1120. 2012.PubMed/NCBI
|
|
21
|
Wang F, He L, Dai W-Q, et al: Salinomycin
inhibits proliferation and induces apoptosis of human
hepatocellular carcinoma cells in vitro and in vivo. PloS One.
7:e506382012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Naujokat C and Steinhart R: Salinomycin as
a drug for targeting human cancer stem cells. J Biomed Biotechnol.
2012:9506582012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang Z, Li Y, Ahmad A, et al: Targeting
miRNAs involved in cancer stem cell and EMT regulation: an emerging
concept in overcoming drug resistance. Drug Resist Updat.
13:109–118. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu J, Kopecková P, Bühler P, et al:
Biorecognition and subcellular trafficking of HPMA
copolymer-anti-PSMA antibody conjugates by prostate cancer cells.
Mol Pharm. 6:959–970. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shen JK, Du HP, Yang M, Wang YG and Jin J:
Casticin induces leukemic cell death through apoptosis and mitotic
catastrophe. Ann Hematol. 88:743–752. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kobayakawa J, Sato-Nishimori F, Moriyasu M
and Matsukawa Y: G2-M arrest and antimitotic activity mediated by
casticin, a flavonoid isolated from Viticis Fructus (Vitex
rotundifolia Linne fil). Cancer Lett. 208:59–64. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mizrak D, Brittan M and Alison M: CD133:
molecule of the moment. J Pathol. 214:3–9. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ma S, Tang KH, Chan YP, et al: miR-130b
promotes CD133(+) liver tumor-initiating cell growth and
self-renewal via tumor protein 53-induced nuclear protein 1. Cell
Stem Cell. 7:694–707. 2010.PubMed/NCBI
|
|
29
|
Li L, Ying J, Li H, et al: The human
cadherin 11 is a pro-apoptotic tumor suppressor modulating cell
stemness through Wnt/beta-catenin signaling and silenced in common
carcinomas. Oncogene. 31:3901–3912. 2012. View Article : Google Scholar : PubMed/NCBI
|
